SPS Commerce to Present at the JMP Securities Technology Conference
Get Alerts SPSC Hot Sheet
Join SI Premium – FREE
MINNEAPOLIS, Feb. 22, 2016 (GLOBE NEWSWIRE) -- SPS Commerce, Inc. (NASDAQ: SPSC), a leading provider of cloud based supply chain management solutions, today announced that management will present at the JMP Securities Technology Conference in San Francisco, CA on Monday, February 29, 2016 at 3:30 p.m. PT.
A webcast of the presentation will be available on the company’s investor relations website at http://investors.spscommerce.com/events.cfm.
About SPS Commerce
SPS Commerce perfects the power of trading partner relationships with the industry's most broadly adopted, retail cloud services platform. As a leader in cloud-based supply chain management solutions, we provide proven integrations and comprehensive retail performance analytics to thousands of customers worldwide. SPS Commerce has achieved 60 consecutive quarters of revenue growth and is headquartered in Minneapolis. For additional information, please contact SPS Commerce at 866-245-8100 or visit www.spscommerce.com.
SPS COMMERCE, SPS, and RETAIL UNIVERSE are marks of SPS Commerce, Inc. and Registered in the U.S. Patent and Trademark Office. 1=INFINITY logo, AS THE NETWORK GROWS, SO DOES YOUR OPPORTUNITY, INFINITE RETAIL POWER, RETAIL UNIVERSE, RSX, SPS logo, and others are further marks of SPS Commerce, Inc. These marks may be registered or otherwise protected in other countries.
Contact: Investor Relations The Blueshirt Group Lisa Laukkanen Nicole Gunderson [email protected] 415-217-7722 Kay Rindels SPS Commerce 866-245-8100 [email protected]Source: SPS Commerce, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- XRP Investors Are Selling at a Loss, According to On-Chain Data
- Tanger Recognized by Newsweek for Workplace Culture and by Nareit for Investor Communications Excellence
- Gan & Lee Pharmaceuticals Achieves Significant Progress in Its Dual Pipeline for Metabolic Diseases -- Weekly Insulin Ludefen (GZR4) Meets Primary Endpoint in Phase III Clinical Trial in China; Bo
Create E-mail Alert Related Categories
Press ReleasesRelated Entities
JMP SecuritiesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share